Diana Isaacs, PharmD, and Natalie Bellini, DNP, review early MiniMed Vivera data on optional meal announcements and twiist's new type 2 diabetes clearance.
|Articles|September 16, 2008
- December15 2004
- Volume 11
- Issue 23
Pharmaceutical Stock Watch
Advertisement
Articles in this issue
about 18 years ago
Steer Clear of Dangerous Tax Promisesabout 18 years ago
Tactfully Time Your Disability Insuranceabout 18 years ago
Safeguard Your Assets with a Solid Wealth Preservation Planabout 18 years ago
Expose Your Portfolio to Foreign Dineroabout 18 years ago
Minimize Irrational Investing Behaviorabout 18 years ago
Model Portfolio Series: Equity Incomeabout 18 years ago
SUV Loophole Tighteningabout 18 years ago
Going DIY on Financesabout 18 years ago
The State of Death Taxesabout 18 years ago
Cost of a WillAdvertisement
Related to this article
Real-world data in 1477 patients on dialysis show tenapanor reduced serum phosphate at 6 months with or without background phosphate binders.
Approval rests on the phase 3 AFFIRM trial, in which 56% of patients reached clinical remission at week 12 vs 30% with placebo.
Jean Elwing, MD, discusses what drove ralinepag's reduction in PAH clinical worsening in ADVANCE Outcomes and where the it could fit if approved.
Jean Elwing, MD, discusses a CHEST 2026 subgroup analysis showing ralinepag reduces clinical worsening in PAH even among patients with low-risk criteria.
Participants described earlier phenotyping, closer tracking of steroid exposure, and recognizing gradual gains on biologic therapy.
Interim IMAgINATION data show the once-monthly factor B antisense therapy sefaxersen reduced proteinuria by 43.1% vs placebo at week 37 in IgA nephropathy.
Interim RAINIER data show povetacicept reduced proteinuria by 52.0% and resolved hematuria in 85% of patients at week 36, ahead of a November PDUFA date.
Advertisement
Advertisement
Trending on HCPLive
1
Retatrutide Lowers Albuminuria, Glomerular Pressure in Obesity and CKD
2
Sleeve Gastrectomy Improves Heart, Kidney MRI Markers in Youth-Onset T2D
3
TELIGAN: Telitacicept Preserves eGFR Through 2 Years in IgA Nephropathy
4
Ravulizumab Receives FDA Accelerated Approval for IgA Nephropathy
5